FDA’s CAR-T safe­ty probe; Ab­b­Vie’s $10B ADC wa­ger; Pfiz­er’s GLP-1 set­back; Ace­lyrin’s CRO dra­ma; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re of­fi­cial­ly in the fi­nal month of the year, and this week, some of the year’s biggest trends are fea­tur­ing in the top head­lines, from GLP-1s to AD­Cs. As you be­gin plan­ning for 2024, do check out our live and vir­tu­al pro­gram­ming at the JP Mor­gan con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER